Blog

Company News

Industry Trends

Laws Regulations

All Categories >

06

2023-09

Little “Life” Makes Sense (IV) | The Advanced Intelligence Agent of Immunotherapy: Dendritic Cells

Dendritic cells (DCs) derive their name from the dendritic processes on their surface, which facilitate antigen capture and intercellular communication with other immune cells. As the most potent professional antigen-presenting cells (APCs), DCs efficiently engulf, process, and present antigens. Immature DCs exhibit robust migratory capacity, whereas mature DCs can effectively activate naïve T cells, thereby occupying a central role in initiating, regulating, and sustaining immune responses. Under normal conditions, DCs are present in low numbers, accounting for only about 1% of peripheral blood mononuclear cells in humans.

2023-09-06

He Yousheng

17

2023-08

Hycells Services | “True” Viral Neutralizing Antibody Testing

Currently, pseudovirus-based assays closely mimic physiological infection mechanisms and can largely replicate the in vivo therapeutic efficacy; however, there is a substantial discrepancy between neutralization assay results obtained with live viruses and those obtained with pseudoviruses. Therefore, live-virus neutralization assays are an indispensable component of antiviral drug and vaccine development.

2023-08-17

He Yousheng

16

2023-08

Little “Life” Makes Sense (III) | The Rising Star of Immunotherapy: γδ T Cells

Immune cells, commonly known as white blood cells, include lymphocytes and various phagocytic cells. They are defined as lymphocytes and other cells capable of recognizing antigens and mounting specific immune responses. Based on their development and migration patterns, surface molecular characteristics, and functional properties, lymphocytes can be classified into T lymphocytes, B lymphocytes, and natural killer (NK) cells.

2023-08-16

He Yousheng

16

2023-08

Anti-FMC63 Antibody | Precise Support for CD19 CAR Cell Therapy Research

CD19 is currently the most widely used target in CAR-T cell therapy, and numerous studies have demonstrated that CD19 is an effective and safe target for the treatment of B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and B-cell lymphomas. FMC63 is a murine monoclonal antibody that targets human CD19. To date, the majority of reported CAR-T clinical trials have constructed CAR-T cells based on the FMC63 antibody sequence, including the two FDA-approved anti-CD19 CAR-T cell therapies, Kymriah and Yescarta. According to the “Research Guidelines on Quality Control Testing and Nonclinical Considerations for CAR-T Cell Therapy Products” issued by the National Institute for Food and Drug Control in 2018, flow cytometry should be used to assess CAR transduction positivity, with preference given to antigen-specific proteins or anti-idiotypic antibodies that exhibit superior specificity for the antigen-binding site.

2023-08-16

He Yousheng

16

2023-08

Hycells Launches a Groundbreaking Product | γδ T (Vγ9Vδ2-T) Cell Expansion Kit

γδ T cells represent an emerging frontier in tumor immunology; like αβ T cells, they can exert cytotoxic effector functions (ADCC) and produce pro-inflammatory cytokines. The key distinction is that γδ T cells recognize tumor antigens in an MHC-unrestricted manner, endowing them with the characteristics of a universal cell therapy product. The TCRγδ on the surface of γδ T cells does not require binding to MHC molecules or antigen presentation by antigen-presenting cells (APCs); instead, it can directly recognize and bind antigenic molecules. However, the repertoire of TCRγδ variants is limited and lacks diversity, resulting in a relatively narrow antigen-recognition spectrum for γδ T cells. γδ T cells in different tissues express distinct TCRγδ receptors and recognize antigens with varying properties, whereas γδ T cells within the same tissue typically express the same TCRγδ and recognize antigens of the same type.

2023-08-16

He Yousheng

03

2023-08

Little “Life” Makes Sense (II) | Double Agent—Treg

Regulatory T cells (also known as Tregs) are a subset of T cells that play a critical role in modulating or suppressing the activity of other immune cells. Tregs regulate immune responses to both self-antigens and foreign antigens, thereby helping to prevent autoimmune diseases. Based on their developmental origin and functional characteristics, Tregs can be classified into two main subsets: natural regulatory T cells (nTregs) and inducible regulatory T cells (iTregs). Both subsets broadly express the transcription factor Foxp3. nTregs develop naturally in the thymus, where their suppressive function is mediated through direct cell–cell contact, whereas iTregs arise from naïve peripheral T cells that are induced by microenvironmental signals in the tumor microenvironment, including tumor-associated antigens, cytokines such as TGF-β, and other soluble factors.

2023-08-03

He Yousheng
< 1...151617...23 >